Neurology in Minnesota

Cretex Medical

Cretex Medical is a division of the Cretex Companies, specializing in end-to-end contract manufacturing for the medical device industry. With over 100 years of history, the company provides critical components, assemblies, packaging, and sterilization services. It supports medical device OEMs from development through to finished device production, emphasizing quality, operational excellence, and innovation. The company operates multiple specialized businesses, including CDT, Quality Tech Services (QTS), rms, and Meier, each offering unique capabilities. CDT focuses on high-precision components and assemblies, while QTS provides end-of-line services such as assembly, packaging, and sterilization validations. rms specializes in tight-tolerance implantable devices and custom instrumentation, and Meier produces micro-sized components for various medical applications. Cretex Medical serves OEMs in sectors like cardiovascular, neuromodulation, orthopedics, and defense, prioritizing long-term partnerships and reliability in manufacturing.

Saluda Medical is a global neuromodulation company headquartered in Bloomington, Minnesota, specializing in advanced spinal cord stimulation (SCS) therapies for chronic pain management. The company's flagship product, the Evoke® System, is the first FDA-indicated closed-loop SCS system that directly senses and measures the spinal cord's physiologic response using Evoked Compound Action Potentials (ECAPs), enabling real-time adjustment of stimulation parameters for optimal therapeutic efficacy. Founded in 2011, Saluda Medical has developed over 15 years of research and clinical experience, with published clinical evidence demonstrating long-term pain relief outcomes extending to 36 months. The company operates across North America, Australia, the United Kingdom, and the Netherlands, serving clinicians and patients seeking alternatives to opioid-based pain management for chronic intractable pain conditions affecting over 540 million people globally.

Dymedix Diagnostics is a Minnesota-based manufacturer of diagnostic sensors for clinical sleep medicine, operating for over 15 years. The company specializes in designing and manufacturing disposable and reusable sleep study sensors using proprietary PVDF (polyvinylidene fluoride) technology. Their product portfolio includes airflow sensors, snore detection sensors, respiratory effort sensors, and surface electrodes used in polysomnography (sleep testing). Key product lines include TriplePlay™ Airflow Sensors, PerfectFit™ Effort Sensors, and AccuSnore™ Snore Sensors. The PVDF-based design provides sensitivity to movement, pressure, strain, temperature, and vibration, enabling accurate waveform capture in sleep diagnostic applications. Dymedix serves sleep medicine laboratories, pulmonology centers, and sleep disorders clinics. The company maintains both disposable and reusable sensor options to meet varied clinical and operational requirements. Products are designed with input from technologists, physicians, and patients to optimize clinical utility and patient comfort.

Fasikl Inc. is a neurotechnology company developing AI-based therapeutic devices for neurological conditions. The company's flagship product, Felix NeuroAI™ Wristband, is a non-invasive wearable device that has received FDA clearance for the treatment of essential tremor. Felix operates through advanced AI technologies that decode and modulate neural signals, delivering all-day symptomatic relief without surgery or medication. The device represents a breakthrough in AI therapeutics, combining cloud-based artificial intelligence with real-time neural signal processing. Fasikl also develops the Fasikl-X™ Nerve-Computer Interface platform for broader neural interfacing applications. The company has invested over 20 years of R&D in neural signal processing and AI-driven treatment modalities. Products are designed for direct patient use and clinical settings, with support for both individual patients and healthcare providers. FDA clearance indicates regulatory approval for the Felix device as a Class II or higher medical device. The company targets essential tremor patients and related neurological indications, positioning itself at the intersection of wearable medical devices, neurotechnology, and artificial intelligence therapeutics.

MeKo Manufacturing e.K. is a contract manufacturer of precision medical components and implants for the interventional and surgical device industry. Founded in 1995, the company pioneered stent manufacturing and is now among the largest contract manufacturers of medical components globally. MeKo specializes in laser cutting, laser welding, and advanced processing of materials including stainless steel (316L, 316LVM), cobalt alloys (L605, Phynox, MP35N), nitinol (NiTi), magnesium alloys (Resoloy®), nickel-free alloys (Vasculoy®), and polymers (PolyMediX®, PLLA, PGA). The company manufactures implants for cardiology, neurology, radiology, ophthalmology, and urology applications, with product lines including metal stents, NiTi stents, hypotubes, retrieval baskets, bone nails, heart valve frames, orthopedic devices, surgical instruments, microcomponents, and drug-delivery balloon catheters. Manufacturing capabilities include CAD/CAM design, precise laser cutting (tolerances below ±5 μm), laser welding, mechanical processing, heat treatment, shape setting, electropolishing, 3D metal printing, polymer coating, marker crimping, and rapid prototyping. The company operates ISO-certified quality management with 100% visual inspection using over 100 specialized high-end microscopes and maintains ISO 8 cleanrooms (Class 100,000). MeKo offers finite element analysis (FEA) simulation services, prototype-to-series production capabilities, and operates 24/7 manufacturing. The company maintains facilities in Germany (Sarstedt, near Hannover), the USA (Bloomington, Minnesota), California, and Costa Rica.

Resolution Medical is a medical device development and manufacturing partner specializing in complex catheter delivery systems, active implantable devices, and component manufacturing. The company serves structural heart, cardiology, vascular, heart failure (VAD), neuromodulation, electrophysiology, and additional specialty markets including ENT, neurology, urology, oncology, endoscopy, and robotics. Core capabilities span the full product lifecycle: concept and design development, BioSimulation and testing with cardiovascular visualization in pressurized heart models, New Product Introduction (NPI) with design-for-manufacturing optimization, and end-to-end manufacturing from prototyping through commercial production. Resolution Medical operates specialized clean rooms, sterile packaging, labeling, and distribution infrastructure. In structural heart, the company develops implants and catheter delivery systems for mitral, tricuspid, aortic, and pulmonary valve interventions, as well as shunts, stents, closure devices, and embolic protection. Cardiology and vascular expertise includes complex delivery platforms, imaging and sensing catheter systems for peripheral, neurovascular, and cardiovascular applications, DVT/PE management, drug delivery, and flow management. Heart failure capabilities encompass VAD pump development, drivelines, and deployment systems. Neuromodulation focus includes Class III active implantables: implantable pulse generators (IPGs), leads, headers, adapters, and subassemblies for spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, and peripheral nerve modulation. Electrophysiology specialization covers diagnostic mapping and energy delivery catheters with modalities including pulsed field ablation (PFA), RF energy, cryotherapy, and vapor therapy. The company maintains a quality management system per ISO 13485:2016 and operates under FDA guidelines. Resolution Medical was recently acquired by Resonetics (2025) and operates with 100+ engineers backed by 1,000+ combined years of experience.

WR Medical Electronics Co. is a manufacturer of autonomic and peripheral neuropathy diagnostic testing systems and software. The company specializes in integrated solutions for quantitative assessment of autonomic dysfunction, syncope, POTS (postural orthostatic tachycardia syndrome), neuropathy, and hyperalgesia. Core product offerings include the WR Head-Up Tilt Table for syncope and POTS evaluation, WR HRV Acquire for heart rate variability and beat-to-beat blood pressure monitoring, WR Q-Sweat QSART (quantitative sudomotor axon reflex test) device for sudomotor assessment, CASE IV Peripheral Testing System for quantitative sensory testing (QST) including vibration, touch, heat, and cooling sensation, and WR Testworks Software for integrated data acquisition and analysis. The company's validated testing protocols combine cardiovagal, sudomotor, and adrenergic assessments into comprehensive clinical reports. WR Medical serves private practices, clinics, hospitals, academic research institutions, universities, and pharmaceutical/clinical trial sponsors. The company offers personalized installation, training, and ongoing technical support. Over 30 years of experience developing solutions in collaboration with autonomic and peripheral neurology pioneers. Customers include facilities at major international medical conferences (AANEM, MEDICA). Products are used for clinical diagnosis, research endpoints, and normative data establishment across multiple geographic populations.

Technical Services for Electronics (TSE), operating as a brand of AMETEK Paragon Medical, is a custom medical device component manufacturer specializing in precision interconnect solutions, cable assemblies, and laser-processed components for leading medical device OEMs. The company provides collaborative engineering and advanced manufacturing capabilities across 40+ years of medical device innovation, serving electrophysiology, neuromodulation, cardiac rhythm management, patient monitoring, vascular, surgical instruments, orthopedic, and structural heart device markets. TSE manufactures components from specialty materials including Nitinol, PEEK, stainless steel, and silicone. Core offerings include custom electrical interconnects, DENSYTY interconnect systems, cable assemblies with smart PCB integration, laser ablation of polymers, fine wire components, catheter manufacturing, Nitinol laser processing, precision tube cutting, laser welding, and laser hole drilling. The company operates as part of AMETEK Inc.'s Paragon Medical division alongside brands Avicenna and Laserage. TSE provides world-class manufacturing with robust quality systems and integrative service models designed to accelerate time-to-market for innovative medical device concepts across multiple clinical specialties.

PMT Corporation, founded in 1979 and based in Chanhassen, Minnesota, is a manufacturer and distributor of specialty medical products and devices. The company focuses on research and development across neurosurgery, plastic and reconstructive surgery, orthopedic medicine, and gastrointestinal endoscopy. PMT's comprehensive product portfolio includes cortical surface electrodes for epilepsy monitoring, neuronavigation depth electrodes (AccuNav®), cervical traction halo fixation systems, tissue and breast expanders for reconstructive surgery, orthopedic collars and lumbo-sacral orthoses, and micropigmentation and dermabrasion devices. The company also manufactures the ALLURA® vaginal stent and Endomark™ gastric ink markers. Supported by a nationwide US and Canadian sales force and global distributor network, PMT provides 24/7 customer support and delivers sterile surgical supplies and specialized instruments to hospitals, surgical centers, and specialty practitioners.

Clarus Medical is an ISO 13485-certified manufacturer of small-diameter, high-quality medical endoscopes with over 30 years of design and manufacturing experience. The company specializes in precision endoscopic devices across four primary clinical domains: airway management (intubation scopes for anesthesia and airway control), spine surgery (minimally invasive surgical instruments), neuroendoscopy (neurosurgical visualization), and industrial inspection borescopes. Products are manufactured in an ISO 13485-certified cleanroom facility to ensure quality and sterility. Beyond direct medical device sales, Clarus Medical offers OEM and private label manufacturing partnerships with leading medical companies, positioning them as both a device innovator and contract manufacturer. The company focuses on minimizing patient trauma, reducing medical costs, and supporting life-saving clinical procedures through precision instrumentation.

CVRx is a medical technology company specializing in neuromodulation therapies for heart failure management. The company's flagship product, Barostim, is an implantable device that delivers gentle electrical pulses to baroreceptors on the carotid artery to modulate neural signals and reduce heart failure symptoms. Clinical evidence demonstrates that Barostim improves exercise capacity (patients walk approximately 60 yards farther in 6-minute testing), quality of life (3x greater improvement vs. medication alone), and symptom relief, with 94% of patients experiencing significant improvement in quality of life, exercise capacity, or heart failure symptoms. The minimally invasive implant procedure typically takes about one hour with same-day discharge and a 97% freedom-from-complications rate. CVRx provides comprehensive support services to healthcare providers, including patient access assistance and reimbursement support to ensure eligible patients can access baroreflex activation therapy.

Nextern Innovation is a vertically integrated medical device contract design, development, and manufacturing organization (CDMO). The company collaborates with innovators and clinicians to design, develop, optimize, and manufacture medical devices across multiple therapeutic areas. Nextern operates four global manufacturing facilities totaling 250,000 square feet, including 20,000 square feet of cleanroom space, with a team of 600+ members worldwide. The company specializes in minimally invasive devices, single-use catheter and metal assemblies, Class III active implantable leads and delivery systems, power systems (catheter and generator development), bioelectronics, and connected care solutions. Nextern Liink, a subsidiary, develops custom, secure, and scalable software solutions for medical device connectivity. Core capabilities include device design and development (bio-simulation, pre-clinical testing, IP support), full-spectrum manufacturing with phased transition from development to commercialization, supply chain management, and life-cycle services including warranty and continuous improvement. The company operates virtual quality management systems and maintains presence in strategically located global manufacturing locations with localized supply chains. Nextern serves cardiology, neuromodulation, and other specialty device markets, with demonstrated expertise in brain-computer interfaces and platforms for labeling and graphical user interfaces.

Pharaoh Neuro, Inc. develops the Neurapheresis™ platform, an investigational extracorporeal cerebrospinal fluid (CSF) filtration therapy designed to remove foreign constituents, pathogens, and blood degradation products from the CSF in neurocritical patients. The company, founded in 2017 as a collaboration between Minnetronix Neuro and Duke University Medical Center, focuses on restoring CSF balance to protect brain health and improve outcomes in patients with acute neurological conditions. Current clinical initiatives include subarachnoid hemorrhage (SAH), cryptococcal meningitis, and leptomeningeal carcinomatosis. The Neurapheresis™ system operates via spinal catheter extension, offering precision management of intracranial pressure and metabolic waste clearance in the neurocritical care setting. The device is currently in clinical investigation under FDA Investigational Device Exemption (IDE) and has not yet received FDA clearance or approval for commercial distribution in the United States.

Welcony is a healthcare technology holding company uniting four distinguished neurotechnology brands: Magstim, EGI, Technomed, and Neurosign. The company offers a comprehensive portfolio of neuromodulation and clinical neurophysiology solutions with over 40 years of combined industry experience and more than 20,000 clinical citations. Magstim specializes in Transcranial Magnetic Stimulation (TMS) technology for mental health treatment and neuroscience research, including pain therapy applications. EGI provides high-definition electroencephalography (HD-EEG) systems for researchers and clinicians. Technomed manufactures high-quality products for clinical neurophysiology and neuromonitoring, including original equipment manufacturer (OEM) and private-label solutions. Neurosign develops nerve monitoring accessories and surgical solutions designed to preserve vital patient nerves during surgical procedures. The company serves clinical, research, and surgical markets across more than 100 regions globally. Products are designed for hospital systems, specialized neurology clinics, research institutions, and surgical centers. The organization emphasizes quality, reliability, and clinical outcomes in neuromonitoring and neurostimulation applications.

NaviNetics Inc. is a medical device company founded by researchers, engineers, and neurosurgeons from the Neural Engineering Laboratories at Mayo Clinic in Rochester, Minnesota. The company specializes in stereotactic neurosurgery systems for precise target localization and patient head fixation during minimally invasive procedures. Their flagship product is the NaviNetics Reusable Stereotactic System, a frame-based neurosurgical targeting platform designed for deep brain stimulation (DBS), lesioning, biopsies, targeted injections, aspirations, and minimally invasive tumor treatments. The system combines the accuracy and workflow efficiency of traditional frame-based systems with a compact, ergonomic design. Key features include skull anchor fixation (eliminating the need for a base frame), intuitive targeting adjustments, excellent burr hole access, and procedural sterile field integrity. The system is compatible with standard CT and MR imaging localizers, enabling planning workflows consistent with conventional DBS frame methodology. Optional adapters support integration with third-party microdrive systems (AO and FHC). The product is designed to improve patient experience, accelerate DBS workflow, and maintain the accuracy verification standards expected in neurosurgical applications. NaviNetics targets hospitals and surgical centers performing stereotactic neurosurgery, with particular focus on DBS programs and functional neurosurgery.

NeuroOne Medical Technologies develops minimally invasive diagnostic and therapeutic neurosurgical devices based on proprietary thin-film electrode technology. The company's primary platform enables high-definition neuronal recording and ablation for functional neurosurgery, with an initial focus on epilepsy and trigeminal neuralgia treatment. Core products include the OneRF® Radiofrequency Ablation System (FDA-cleared K231675 for functional neurosurgical procedures; K251243 for trigeminal nerve ablation), which uniquely performs both diagnostic mapping and therapeutic ablation using the same stereotactic electroencephalography (sEEG) electrode. The Evo® sEEG System (FDA-cleared K222404) provides temporary subsurface brain recording, monitoring, and stimulation, while the Evo® Cortical Electrodes (FDA-cleared K192764) offer surface brain recording with reduced immunological response and improved cable management. NeuroOne's flexible thin-film electrode platform is designed to provide higher-resolution neural signal acquisition compared to conventional rigid electrodes, potentially reducing infection risk and procedure complexity. The company is developing a comprehensive portfolio for neurological applications beyond epilepsy, working with leading neurosurgical centers including Mayo Clinic. All devices are subject to federal restriction to sale by or on the order of a physician.

Monteris Medical Corp is a leader in minimally invasive laser ablation technology for neurosurgical applications. The company specializes in laser interstitial thermal therapy (LITT) systems designed specifically for brain procedures. Their flagship product, the NeuroBlate System, is an MR-guided robotic laser ablation platform indicated for treatment of brain tumors, radiation necrosis, and drug-resistant epilepsy. The system represents the only robotic MR-guided laser ablation tool in its class, delivering real-time thermal imaging and precision ablation capabilities for neurosurgical oncology and epilepsy applications. Monteris is committed to prospective multi-center clinical evidence generation, including participation in landmark studies such as LAANTERN to establish the safety and efficacy profile of LITT in brain applications. The company serves neurosurgical centers, academic medical centers, and specialized treatment facilities performing minimally invasive brain procedures. Products are designed for use in intraoperative MRI environments with integrated navigation and thermal monitoring. The company maintains a collaborative, innovation-focused organizational structure supporting product development and clinical evidence generation for minimally invasive neuroablation.

Neuros Medical Inc. manufactures the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable neuromodulation device designed for chronic post-amputation pain management in adult lower limb amputees. The Altius system provides on-demand pain relief for phantom limb pain and residual limb pain through patient-controlled electrical stimulation delivered directly to affected nerves via an implantable pulse generator and wireless controller. The system enables patients to initiate therapy when needed without scheduled treatments. Clinical evidence from the QUEST study (180 patients) demonstrated significant therapeutic outcomes: 44% improvement in walking ability, 51% improvement in sleep quality, and 45% improvement in overall quality of life. Patients achieved approximately 30% pain reduction within 30 minutes of therapy initiation and approximately 50% pain reduction at 120 minutes. The device is indicated as an aid in managing chronic intractable phantom and residual lower limb post-amputation pain. FDA approval reflects successful demonstration of safety and effectiveness, though the agency imposed a post-market condition requiring human factors engineering and usability validation testing per FDA's 2016 guidance. The company markets directly to eligible amputees and coordinates with healthcare providers for surgical implantation and ongoing management. Contraindications include patient inability to operate the system and unsuitability for implant surgery. Key safety considerations include incompatibility with diathermy, potential electromagnetic interference, cardiac device interactions, contraindication for MRI/NMRI, and increased adverse event frequency in diabetic patients.